obesitycast.com 

 cme
 

Obesity Cast Circle
Translating Trial-Based Evidence and Real World Data for Sensor-Based Glucose Monitoring Critical Advances in Flash-Based CGM: A Foundational Approach to Optimizing Health Metrics and Costs Across the Entire Spectrum of Diabetes Care
Translating Trial-Based Evidence and Real World Data for Sensor-Based Glucose Monitoring Optimizing the Use of Sensor-Based Glucose Monitoring in the Primary Care Setting
Sensor-Based Glucose Monitoring to the Front Lines of Pharmacy Management Trial-Based Evidence and Real World Data for Sensory-Based Glucose Monitoring at the Front Lines of Diabetes Care
Optimizing Referral, Management and Treatment Strategies for Diabetic Macular Edema (DME) Critical Advances in Mitigating Progression of Diabetic Eye Disease
The Optometrist's Critical Role in Screening, Diagnosis, and Referring Patients with Diabetic Retinopathy New Blindness-Prevention Treatment Stratgies for Diabetic Retinopaythy (DR) Webinar 5 of 9
Sensor-Based CGM Across the Diabetes Treatment Spectrum
Interpretation of Sensor-Based Glucose Metrics, Time in Range (TIR) and Ambulatory Glucose Profiles (AGP) Combination Therapy with DTE in Appropriately Selected Patients wtih Hypothyroidism

Applying Clinical Evidence for Sensor-Based Glucose Monitoring

 Clinical Evidence for Sensor-Based Glucose Monitoring and Technological innovations

Technological Innovations in Sensor-Based Glucose Monitoring

 From Landmark CV Outcome Trials to the Front Lines of ASCVD Risk Reduction - Program 4 in a Four-part series

Translating Clinical Evidence for Sensor-Based Glucose Monitoring and Technological Innovations

Fixed-Ratio Combination Basal Insulin plus GLP-1 RA Regimens

Technology-Based Innovations in Continuous Glucose Monitoring (CGM).

PCSK9 Inhibition in the Diabetic Patient

Translating Clinical Evidence for Sensor-Based Glucose Monitoring and Technological Innovations to the Front Lines of Clinical Practice

 Complementary Insulin Combinations to Optimize Glycemic Control in T2D

Physiologic, Ultra-Long-Acting Basal Insulin in Vulnerable Patients with T2D

UMASS

More CME Programs